Objectives. To systematically review and meta-analyse evidence on the effectiveness of the TNF-α inhibitors when used sequentially

A. J. Sutton

A. J. Wailoo

Abrams

Bingham

Buch

Cohen

D. Scott

Di Poi

Finckh

Genovese

Haraoui

Keystone

Klareskog

Laas

Navarro-Saarabia

Plenge

Pugner

S. Bujkiewicz

S. Lloyd

Scott

St Clair

Symmons

SYMMONS

van der Bijl

van Vollenhoven

Wick

Wiles

Crossref

PubMed Central

Enlighten

King's Research Portal

White Rose Research Online

Leicester Research Archive

English

a human TNF-alpha monoclonal antibody, in rheumatoid arthritis patients previously treated with anti-TNF-alphaagents (Go-After Study). Rheumatology

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

Adalimumab in clinical practice.

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: Relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008;27:

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum

Biologic drugs for rheumatoid arthritis in the Medicare program: a cost effectiveness analysis. Arthritis Rheum

c-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists.

Drosos A et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-Week, open-label, observational study.

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis

et al.D o rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis

Etanercept maintains the clinical benefit achieved by infliximab in

Evaluating the sequential use of TNF-alpha Inhibitors.

Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions.

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.

Lloyd et al.patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007;66:

Meta-analysis of heterogeneously reported trials assessing change from baseline. Stat Med

Methods for meta-analysis in medical research.

Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis

NICE guidelines on anti-tumor necrosis factor therapy for RA. Nat Clin Pract Rheumatol 2009;5:

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.

rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum

Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol

The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol

The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register.

The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomised controlled trial.

Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007;57:

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology

Treatment with infliximab when etanercept has fialed or visa versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis.

www.rheumatology.oxfordjournals.org 2321 Effectiveness of anti-TNF-a therapies

The effectiveness of anti-TNF-α therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis